Oncolytics raises $24M for cancer trial

Canada's Oncolytics, which is developing oncolytic viruses as potential cancer therapeutics, has raised about $24 million through the sale of 5.44 million units of the company's stock for $4.60 each. The underwriters--which include Paradigm Capital, RBC Capital Markets, Canaccord Genuity Corp and Bloom Burton & Co--have an option to purchase another 15 percent at the same price.

The company plans to use the money to fund ongoing Phase III combination Reolysin and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, other clinical development and R&D activities, and for general corporate and working capital purposes, Oncolytics said in a statement.

 - check out Oncolytics' release
- here's the Reuters report

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.